A 5-Genomic Mutation Signature Can Predict the Survival for Patients With NSCLC Receiving Atezolizumab

BACKGROUND: At present, there is a lack of studies focusing on the survival prediction of patients with non-small cell lung cancer (NSCLC) receiving atezolizumab in light of gene mutation characteristic. METHODS: Patients with NSCLC receiving atezolizumab from the OAK study were defined as the train...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Front Immunol
Hoofdauteurs: Lin, Jiamao, Wang, Xiaohui, Zhang, Chenyue, Bu, Shuai, Zhao, Chenglong, Wang, Haiyong
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Frontiers Media S.A. 2021
Onderwerpen:
Immunology
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8261129/
https://ncbi.nlm.nih.gov/pubmed/34248926
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2021.606027
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items